Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer

C Coulson-Gilmer, M P Humphries, S Sundara Rajan, A Droop, S Jackson, A Condon, G Cserni, L B Jordan, J L Jones, R Kanthan, A Di Benedetto, M Mottolese, E Provenzano, J Kulka, A M Shaaban, A M Hanby, V Speirs

Research output: Contribution to journalArticle

2 Citations (Scopus)
4 Downloads (Pure)

Abstract

Breast cancer can arise in either gender; however, it is rare in men, accounting for <1% of diagnosed cases. In a previous transcriptomic screen of male and female breast cancer we observed that Stanniocalcin 2 (STC2) was overexpressed in the former. The aim of this study was to confirm the expression of STC2 in male breast cancer, and to investigate whether this had an impact on patient prognosis. Following an earlier transcriptomic screen, STC2 gene expression was confirmed by RT-qPCR in matched male and female BC samples as well as in tumour-associated fibroblasts derived from each gender. Subsequently, STC2 protein expression was examined immunohistochemically in tissue microarrays containing 477 male breast cancer cases. Cumulative survival probabilities were calculated using the Kaplan-Meier method and multivariate survival analysis was performed using the Cox hazard model. Gender-specific STC2 gene expression showed a 5.6-fold upregulation of STC2 transcripts in male breast cancer, also supported by data deposited in OncomineTM . STC2 protein expression was a positive prognostic factor for disease-free survival (Log rank; total p=0.035, HR=0.49; tumour cells p=0.017, HR=0.44; stroma p=0.030, HR=0.48), but had no significant impact on overall survival (Log rank; total p=0.23, HR=0.71; tumour cells p=0.069, HR=0.59; stroma p=0.650, HR=0.87). Importantly, multivariate analysis adjusted for patient age at diagnosis, node staging, tumour size, ER and PR status revealed that total STC2 expression as well as expression in tumour cells was an independent prognostic factor for disease-free survival (Cox regression; p=0.018, HR=0.983; p=0.015, HR=0.984 respectively). In conclusion STC2 expression is abundant in male breast cancer where it is an independent prognostic factor for disease-free survival. This article is protected by copyright. All rights reserved.

Original languageEnglish
Pages (from-to)241-249
Number of pages9
JournalThe Journal of Pathology. Clinical Research
Volume4
Issue number4
Early online date23 Aug 2018
DOIs
Publication statusPublished - Oct 2018

Fingerprint

Male Breast Neoplasms
Disease-Free Survival
Proportional Hazards Models
Multivariate Analysis
Gene Expression
teleocalcin
Neoplasms
Survival
Neoplasm Staging
Survival Analysis
Proteins
Up-Regulation
Breast Neoplasms

Keywords

  • Journal Article
  • male breast cancer
  • stanniocalcin 2
  • immunochemistry
  • survival

Cite this

Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer. / Coulson-Gilmer, C; Humphries, M P; Sundara Rajan, S; Droop, A; Jackson, S; Condon, A; Cserni, G; Jordan, L B; Jones, J L; Kanthan, R; Di Benedetto, A; Mottolese, M; Provenzano, E; Kulka, J; Shaaban, A M; Hanby, A M; Speirs, V.

In: The Journal of Pathology. Clinical Research, Vol. 4, No. 4, 10.2018, p. 241-249.

Research output: Contribution to journalArticle

Coulson-Gilmer, C, Humphries, MP, Sundara Rajan, S, Droop, A, Jackson, S, Condon, A, Cserni, G, Jordan, LB, Jones, JL, Kanthan, R, Di Benedetto, A, Mottolese, M, Provenzano, E, Kulka, J, Shaaban, AM, Hanby, AM & Speirs, V 2018, 'Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer', The Journal of Pathology. Clinical Research, vol. 4, no. 4, pp. 241-249. https://doi.org/10.1002/cjp2.106
Coulson-Gilmer C, Humphries MP, Sundara Rajan S, Droop A, Jackson S, Condon A et al. Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer. The Journal of Pathology. Clinical Research. 2018 Oct;4(4):241-249. https://doi.org/10.1002/cjp2.106
Coulson-Gilmer, C ; Humphries, M P ; Sundara Rajan, S ; Droop, A ; Jackson, S ; Condon, A ; Cserni, G ; Jordan, L B ; Jones, J L ; Kanthan, R ; Di Benedetto, A ; Mottolese, M ; Provenzano, E ; Kulka, J ; Shaaban, A M ; Hanby, A M ; Speirs, V. / Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer. In: The Journal of Pathology. Clinical Research. 2018 ; Vol. 4, No. 4. pp. 241-249.
@article{e5244fd189cc41c294825b366211a4e6,
title = "Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer",
abstract = "Breast cancer can arise in either gender; however, it is rare in men, accounting for <1{\%} of diagnosed cases. In a previous transcriptomic screen of male and female breast cancer we observed that Stanniocalcin 2 (STC2) was overexpressed in the former. The aim of this study was to confirm the expression of STC2 in male breast cancer, and to investigate whether this had an impact on patient prognosis. Following an earlier transcriptomic screen, STC2 gene expression was confirmed by RT-qPCR in matched male and female BC samples as well as in tumour-associated fibroblasts derived from each gender. Subsequently, STC2 protein expression was examined immunohistochemically in tissue microarrays containing 477 male breast cancer cases. Cumulative survival probabilities were calculated using the Kaplan-Meier method and multivariate survival analysis was performed using the Cox hazard model. Gender-specific STC2 gene expression showed a 5.6-fold upregulation of STC2 transcripts in male breast cancer, also supported by data deposited in OncomineTM . STC2 protein expression was a positive prognostic factor for disease-free survival (Log rank; total p=0.035, HR=0.49; tumour cells p=0.017, HR=0.44; stroma p=0.030, HR=0.48), but had no significant impact on overall survival (Log rank; total p=0.23, HR=0.71; tumour cells p=0.069, HR=0.59; stroma p=0.650, HR=0.87). Importantly, multivariate analysis adjusted for patient age at diagnosis, node staging, tumour size, ER and PR status revealed that total STC2 expression as well as expression in tumour cells was an independent prognostic factor for disease-free survival (Cox regression; p=0.018, HR=0.983; p=0.015, HR=0.984 respectively). In conclusion STC2 expression is abundant in male breast cancer where it is an independent prognostic factor for disease-free survival. This article is protected by copyright. All rights reserved.",
keywords = "Journal Article, male breast cancer, stanniocalcin 2, immunochemistry, survival",
author = "C Coulson-Gilmer and Humphries, {M P} and {Sundara Rajan}, S and A Droop and S Jackson and A Condon and G Cserni and Jordan, {L B} and Jones, {J L} and R Kanthan and {Di Benedetto}, A and M Mottolese and E Provenzano and J Kulka and Shaaban, {A M} and Hanby, {A M} and V Speirs",
note = "Funding Information Breast Cancer Now. Grant Number: TBLEE2017 Yorkshire Cancer Research. Grant Number: L378",
year = "2018",
month = "10",
doi = "10.1002/cjp2.106",
language = "English",
volume = "4",
pages = "241--249",
journal = "The Journal of Pathology. Clinical Research",
issn = "2056-4538",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer

AU - Coulson-Gilmer, C

AU - Humphries, M P

AU - Sundara Rajan, S

AU - Droop, A

AU - Jackson, S

AU - Condon, A

AU - Cserni, G

AU - Jordan, L B

AU - Jones, J L

AU - Kanthan, R

AU - Di Benedetto, A

AU - Mottolese, M

AU - Provenzano, E

AU - Kulka, J

AU - Shaaban, A M

AU - Hanby, A M

AU - Speirs, V

N1 - Funding Information Breast Cancer Now. Grant Number: TBLEE2017 Yorkshire Cancer Research. Grant Number: L378

PY - 2018/10

Y1 - 2018/10

N2 - Breast cancer can arise in either gender; however, it is rare in men, accounting for <1% of diagnosed cases. In a previous transcriptomic screen of male and female breast cancer we observed that Stanniocalcin 2 (STC2) was overexpressed in the former. The aim of this study was to confirm the expression of STC2 in male breast cancer, and to investigate whether this had an impact on patient prognosis. Following an earlier transcriptomic screen, STC2 gene expression was confirmed by RT-qPCR in matched male and female BC samples as well as in tumour-associated fibroblasts derived from each gender. Subsequently, STC2 protein expression was examined immunohistochemically in tissue microarrays containing 477 male breast cancer cases. Cumulative survival probabilities were calculated using the Kaplan-Meier method and multivariate survival analysis was performed using the Cox hazard model. Gender-specific STC2 gene expression showed a 5.6-fold upregulation of STC2 transcripts in male breast cancer, also supported by data deposited in OncomineTM . STC2 protein expression was a positive prognostic factor for disease-free survival (Log rank; total p=0.035, HR=0.49; tumour cells p=0.017, HR=0.44; stroma p=0.030, HR=0.48), but had no significant impact on overall survival (Log rank; total p=0.23, HR=0.71; tumour cells p=0.069, HR=0.59; stroma p=0.650, HR=0.87). Importantly, multivariate analysis adjusted for patient age at diagnosis, node staging, tumour size, ER and PR status revealed that total STC2 expression as well as expression in tumour cells was an independent prognostic factor for disease-free survival (Cox regression; p=0.018, HR=0.983; p=0.015, HR=0.984 respectively). In conclusion STC2 expression is abundant in male breast cancer where it is an independent prognostic factor for disease-free survival. This article is protected by copyright. All rights reserved.

AB - Breast cancer can arise in either gender; however, it is rare in men, accounting for <1% of diagnosed cases. In a previous transcriptomic screen of male and female breast cancer we observed that Stanniocalcin 2 (STC2) was overexpressed in the former. The aim of this study was to confirm the expression of STC2 in male breast cancer, and to investigate whether this had an impact on patient prognosis. Following an earlier transcriptomic screen, STC2 gene expression was confirmed by RT-qPCR in matched male and female BC samples as well as in tumour-associated fibroblasts derived from each gender. Subsequently, STC2 protein expression was examined immunohistochemically in tissue microarrays containing 477 male breast cancer cases. Cumulative survival probabilities were calculated using the Kaplan-Meier method and multivariate survival analysis was performed using the Cox hazard model. Gender-specific STC2 gene expression showed a 5.6-fold upregulation of STC2 transcripts in male breast cancer, also supported by data deposited in OncomineTM . STC2 protein expression was a positive prognostic factor for disease-free survival (Log rank; total p=0.035, HR=0.49; tumour cells p=0.017, HR=0.44; stroma p=0.030, HR=0.48), but had no significant impact on overall survival (Log rank; total p=0.23, HR=0.71; tumour cells p=0.069, HR=0.59; stroma p=0.650, HR=0.87). Importantly, multivariate analysis adjusted for patient age at diagnosis, node staging, tumour size, ER and PR status revealed that total STC2 expression as well as expression in tumour cells was an independent prognostic factor for disease-free survival (Cox regression; p=0.018, HR=0.983; p=0.015, HR=0.984 respectively). In conclusion STC2 expression is abundant in male breast cancer where it is an independent prognostic factor for disease-free survival. This article is protected by copyright. All rights reserved.

KW - Journal Article

KW - male breast cancer

KW - stanniocalcin 2

KW - immunochemistry

KW - survival

U2 - 10.1002/cjp2.106

DO - 10.1002/cjp2.106

M3 - Article

VL - 4

SP - 241

EP - 249

JO - The Journal of Pathology. Clinical Research

JF - The Journal of Pathology. Clinical Research

SN - 2056-4538

IS - 4

ER -